For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presen ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.